Sequestered naltrexone in sustained release morphine or oxycodone – a way to inhibit illicit use?

Bibliography

• The American Academy of Pain Medicine. AAPM facts and figures on pain.2013. Available from: http://www.painmed.org/patientcenter/facts_on_pain.aspx [Accessed 11 April 2013]
   Google Scholar
• Institute of Medicine Report from the Committee on Advancing Pain Research. Relieving pain in America, a blueprint for transforming prevention, care, education and research. The National Academies Press; Washington, D.C: 2011
   Google Scholar
• Johannes CB, Le TK, Zhou X, et al. The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 2010;11(11):1230-9
   PubMed Web of Science ®Google Scholar
• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10(4):287-333
   PubMed Web of Science ®Google Scholar
• Sjogren P, Ekholm O, Peuckmann V, et al. Epidemiology of chronic pain in Denmark: an update. Eur J Pain 2009;13(3):287-92
   PubMed Web of Science ®Google Scholar
• Rustoen T, Wahl AK, Hanestad BR, et al. Prevalence and characteristics of chronic pain in the general Norwegian population. Eur J Pain 2004;8(6):555-65
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Fellows B, Ailinani H, et al. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010;13(5):401-35
   PubMed Web of Science ®Google Scholar
• Paulozzi LJ, Jones CM, Mack KA, et al. Vital signs: overdoses of prescription opioid pain relievers — United States, 1999 – 2008. MMWR 2011;60(43):1487-92
   PubMedGoogle Scholar
• Okie S. A. Flood of opioids, a rising tide of deaths. N Engl J Med 2010;363(21):1981-5
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality (CBHSQ), Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2011 national survey on drug use and health: summary of national findings. US Department of Health and Human Services; Rockville, MD: 2012
   Google Scholar
• Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011;37(4):205-17
   PubMed Web of Science ®Google Scholar
• Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010;70(13):1657-75
   PubMed Web of Science ®Google Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013;14(4):351-8
   PubMed Web of Science ®Google Scholar
• Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 1987;102(4):426-9
   PubMed Web of Science ®Google Scholar
• Mammen K, Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother 2009;10(15):2537-44
   PubMed Web of Science ®Google Scholar
• Leri F, Burns LH. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats. Pharmacol Biochem Behav 2005;82(2):252-62
   PubMed Web of Science ®Google Scholar
• Tompkins DA, Lanier RK, Harrison JA, et al. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone. Psychopharmacology (Berl) 2010;210(4):471-80
   PubMed Web of Science ®Google Scholar
• Hamann SR, Malik H, Sloan JW, et al. Interactions of "ultra-low" doses of naltrexone and morphine in mature and young male and female rats. Receptors Channels 2004;10(2):73-81
   PubMedGoogle Scholar
• Mattioli TA, Milne B, Cahill CM. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol Pain 2010;6:22
   PubMed Web of Science ®Google Scholar
• McNaull B, Trang T, Sutak M, et al. Inhibition of tolerance to spinal morphine antinociception by low doses of opioid receptor antagonists. Eur J Pharmacol 2007;560(2-3):132-41
   PubMed Web of Science ®Google Scholar
• Olmstead MC, Burns LH. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology (Berl) 2005;181(3):576-81
   PubMed Web of Science ®Google Scholar
• Powell KJ, Abul-Husn NS, Jhamandas A, et al. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats. J Pharmacol Exp Ther 2002;300(2):588-96
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Draft: guidance for industry - assessment of abuse potential of drugs. 2010
   Google Scholar
• Webster LR. Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs 2007;16(8):1277-83
   PubMed Web of Science ®Google Scholar
• Smith HS. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing. Expert Opin Pharmacother 2011;12(7):1111-25
   PubMed Web of Science ®Google Scholar
• Ruan X. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond. Expert Opin Pharmacother 2011;12(7):999-1001
   PubMed Web of Science ®Google Scholar
• Phizer, Inc. Medication Guide: EMBEDA® (morphine sulfate and naltrexone hydrochloride) extended - release capsules,for oral use, CII. 2009
   Google Scholar
• Jang DH, Rohe JC, Hoffman RS, et al. Severe opioid withdrawal due to misuse of new combined morphine and naltrexone product (Embeda). Ann Emerg Med 2010;55(3):303-4
   PubMed Web of Science ®Google Scholar
• Johnson FK, Stark JG, Bieberdorf FA, et al. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther 2010;32(6):1149-64
   PubMed Web of Science ®Google Scholar
• Johnson F, Setnik B. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability. Pain Physician 2011;14(4):391-406
   PubMed Web of Science ®Google Scholar
• Johnson FK, Ciric S, Boudriau S, et al. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA(R)) and an extended release morphine sulfate capsule formulation (KADIAN(R)) in healthy adults under fasting conditions. Am J Ther 2011;18(1):2-8
   PubMed Web of Science ®Google Scholar
• Stauffer J, Setnik B, Sokolowska M, et al. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 2009;29(12):777-90
   PubMed Web of Science ®Google Scholar
• Webster LR, Johnson FK, Stauffer J, et al. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D 2011;11(3):259-75
   PubMedGoogle Scholar
• Katz N, Sun S, Johnson F, et al. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain 2010;11(4):303-11
   PubMed Web of Science ®Google Scholar
• Katz N, Hale M, Morris D, et al. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgrad Med 2010;122(4):112-28
   PubMed Web of Science ®Google Scholar
• Webster LR, Brewer R, Wang C, et al. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. J Pain Symptom Manage 2010;40(5):734-46
   PubMed Web of Science ®Google Scholar
• Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010(1):CD006605
   PubMed Web of Science ®Google Scholar
• Badalamenti VC, Buckley JW, Smith ET. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of postmarketing adverse events during the first year. J Opioid Manag 2012;8(2):115-25
   PubMedGoogle Scholar
• Johnson FK, Ciric S, Boudriau S, et al. Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. J Clin Pharmacol 2012;52(5):747-56
   PubMed Web of Science ®Google Scholar
• Chindalore VL, Craven RA, Yu KP, et al. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain 2005;6(6):392-9
   PubMed Web of Science ®Google Scholar
• Webster LR, Butera PG, Moran LV, et al. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain 2006;7(12):937-46
   PubMed Web of Science ®Google Scholar
• Spierings ELH, Butera PG, Wu N, et al. Phase III study to assess physical dependence and analgesic effi cacy of Oxytrex versus oxycodone. Presented at the 25th Annual Scientific Meeting of the American Pain Society Poster 814; San Antonio, Texas; 2006
   Google Scholar
• Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain 2007;23(1):15-22
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Nicholson BD, Todd KH, et al. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther 2008;15(4):312-20
   PubMed Web of Science ®Google Scholar
• Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008;11(2 Suppl):S5-S62
   PubMed Web of Science ®Google Scholar
• Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007;23(2):103-18
   PubMed Web of Science ®Google Scholar
• Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther 2000;17(2):70-83
   PubMed Web of Science ®Google Scholar
• Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005;6(2):107-12
   PubMed Web of Science ®Google Scholar
• McCracken LM, Hoskins J, Eccleston C. Concerns about medication and medication use in chronic pain. J Pain 2006;7(10):726-34
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Pappagallo M, Stauffer J, et al. The role of urine drug testing for patients on opioid therapy. Pain Pract 2010;10(6):497-507
   PubMed Web of Science ®Google Scholar
• Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J 1995;94(3):135-40
   PubMedGoogle Scholar
• Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. Pain Physician 2011;14(2):123-43
   PubMed Web of Science ®Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003;35(2):253-9
   PubMed Web of Science ®Google Scholar